Monday, 16 May 2022

Lupin partners with TTP for soft-mist inhalation tech platform

02 December 2021 | News

To complement Lupin’s portfolio of complex inhalation products

Image credit: shutterstock.com

Image credit: shutterstock.com

Lupin has entered into an agreement with TTP (The Technology Partnership) to acquire the exclusive worldwide rights to develop, manufacture and commercialise inhalation products using TTP’s soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.

Soft-mist inhalation (SMI) technology allows for the delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Mumbai-based pharma firm Lupin anticipates applications across respiratory care.

Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialise the products globally.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account